Growth Interrupted: Sustaining The Israeli Life Science Innovation Engine
Executive SummaryMaximizing the productivity of life science innovation hubs across the globe is of ever increasing importance to the continued vitality of the life science products industry. Israel's culture of innovation has produced a large number of start-up companies and product ideas, particularly in medical devices, but Israel has developed remarkably few mature life science companies. One major historical factor preventing Israeli start-ups from maturing into later stage companies is the absence of significant growth capital necessary to finance this kind of company development, which has lead to what the authors term an ongoing market failure. The authors argue that both private and public action is necessary to address this market failure in Israel, and that such action will benefit both that country and the industry as a whole by maintaining this fertile source of life science innovation.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.